October 11, 2017

Protagonist Therapeutics Prices Public Offering of Common Stock read more

October 11, 2017

Protagonist Therapeutics Announces Proposed Public Offering of Common Stock read more

September 20, 2017

Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 read more